One of the hottest areas that opens up is at the junction of CRISPR technology and microbiome-based therapeutics in the rapidly growing horizon of medical research. This ranges from some genetic diseases to chronic diseases influenced by microbial communities and, therefore, holds much promise therapeutically with mechanisms of precision gene editing mediated by CRISPR-Cas9 and manipulation of the microbiome. This new technology has broken the barriers of precision genome alteration with unprecedented accuracy and efficiency for mankind, and this is something that the CRISPR-Cas9 technology goes beyond. The potential of CRISPR in terms of altering specific DNA sequences looks promising regarding the possibility of making cellular processes more effective, correcting genetic defects responsible for inherited diseases, and advancing discoveries on new medicines. Billions of bacteria live in and on part of the human body. As such, the microbiome is the central aspect of disease states and general health. Technological advances in the omics field-transcriptomics, proteomics, metabolomics, and genomes make it currently possible to offer highly detailed molecular medicine. <!----> <!----> <!----> <!---->
It is noteworthy that regulatory science affiliates law and politics with science, and is indispensable to preserve and ensure the understanding of the population health, as well as the guaranteed effectiveness and safety of a procedure or a product. The policy areas include developing technology, food and agriculture, medicine and medical devices and the environment. Opportunities and problems are: rapid technological growth, effective market globalization, and advanced scientific development. This chapter addresses the present and future contingents of Regulatory Aspects 20 in the Pharmaceutical World. A case of challenges involved and perspectives drawn paint the picture of the development of the pharmaceutical control in history. The chapter explores new methodological approaches and a technology affecting the regulation processes, identifies further regulation trends, and provides recommendations for the future of pharmaceutical regulations. <!----> <!----> <!----> <!---->